Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma

Glioblastoma (GBM) is the most common and aggressive adult primary brain tumor [1,2]. Although radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ) has increased patient survival, long-term prognosis remains poor, with a median survival of 15 months [3,4]. Tumor progression most often occurs inside the irradiated tumor volume [5], showing the high radioresistance of these tumors. Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in the regulation of cell proliferation, survival and differentiation.

Source: Radiotherapy and Oncology - September 21, 2020 Category: Radiology Authors: J. Biau, E. Thivatx, E. Chautard, D. Stefan, M. Boone, B. Chauffert, C. Bourgne, D. Richard, I. Molna, S. Levesque, R. Bellini, F. Kwiatkowski, L Karayan-Tapon, P. Verrelle, C. Godfraind, X. Durando Tags: Original Article Source Type: research